Categories
Top Stories Business & Economy Opinion & Editorials Politics Science & Health US News 🔥 Trending

Tylenol, Autism & Trump: Panic, Stocks, and a New Wave of Questions

September 2025: One short announcement from President Trump has turned Tylenol into the biggest health headline of the year. Within hours of his warning, parents were googling “Tylenol autism risk,” Kenvue’s stock price tanked, and autism advocacy groups scrambled to calm the storm.

The drama didn’t end at the White House. It spilled into homes, hospitals, and Wall Street trading desks.

What Trump Said about Autism & Tylenol?

“Don’t take Tylenol. Don’t take it,” Trump said, adding that parents should avoid letting doctors “pump your baby up with the largest pile of stuff” when it comes to vaccines.

Tylenol’s Parent Company Johnson & Johnson is Under Pressure

Tylenol isn’t just a household medicine — it’s also a massive business. The drug is owned by Kenvue (KVUE), which spun off from Johnson & Johnson (JNJ) in 2023.

  • Investors saw billions wiped out in minutes as KVUE stock slumped.
  • Analysts rushed to reassure that “no new science” had been presented.
  • JNJ shares also slipped as traders feared more lawsuits.

This isn’t the first time Tylenol has faced lawsuits over autism, but Trump’s words gave those legal battles new energy.

Tylenol, Autism Questions Go Global

Trump’s comments reopened old debates far beyond America:

  • Amish autism myths resurfaced online, with people claiming low autism rates in Amish communities prove vaccines or Tylenol are the problem. Experts quickly corrected this — pointing out that autism is often underdiagnosed, not absent.
  • Cuba’s autism rates trended briefly after social media users compared U.S. data with Cuban studies, highlighting how reporting systems — not Tylenol — explain differences.
  • Autism researchers stressed again: genetics, environment, and complex factors drive autism. There is no single pill or vaccine behind it.

Culture, Memes & Mispronunciations: acetaminophen

Oddly, what went most viral wasn’t the science. It was Trump’s struggle to say “acetaminophen.” Clips of him mangling the word flooded TikTok, sparking memes with captions like “President can’t pronounce it but wants you to stop taking it.”

For many, that slip summed up the problem — a serious health issue turned into a spectacle.

The Pregnancy Panic

Doctors say the biggest concern now is confusion among expectant mothers. Many are asking: Should I stop Tylenol completely?

  • Some OB-GYNs report patients calling in scared to even take a single dose for fever.
  • Experts warn: untreated fever in pregnancy can be more dangerous than Tylenol itself.

The message from doctors: don’t panic, talk to your physician, and don’t base pregnancy decisions on press conferences.

The Bigger Picture

Trump’s announcement may fade from the news cycle, but the aftershocks are real:

  • More lawsuits will likely pile up against Tylenol.
  • FDA label changes could spook consumers further.
  • Autism causes will remain one of the most misunderstood — and exploited — debates in medicine.

Checkout this post: What Trump Said about Autism & Tylenol?

Read more at: Todaybeat.com

👉 For now, Tylenol sits at the messy crossroads of politics, science, and business. And the question hanging in the air is simple: who will parents believe — their doctors, or their president?

acetaminophenAutismPresident Donald TrumpTrumpTylenolWhite House announcement

Categories
Business & Economy Opinion & Editorials Politics Stock Market Top Stories US News World News 🔥 Trending

Trump Links Autism to Tylenol and Vaccines — Experts Say Claims Not Backed by Science

Washington, Sept 22, 2025: In a dramatic White House announcement, President Donald Trump warned pregnant women against using Tylenol and raised new doubts about routine childhood vaccines. Standing alongside Health Secretary Robert F. Kennedy Jr., Trump said the popular pain reliever — known generically as acetaminophen (pronounced uh-SEE-tuh-MEE-nuh-fen) — may be linked to autism in children.

But here’s the catch: scientists, doctors, and Tylenol’s maker Kenvue (NYSE: KVUE, a spinoff from Johnson & Johnson, JNJ) say decades of research show no causal link.

What Trump Said about Autism & Tylenol?

“Don’t take Tylenol. Don’t take it,” Trump said, adding that parents should avoid letting doctors “pump your baby up with the largest pile of stuff” when it comes to vaccines.

  • Trump also pushed splitting the MMR vaccine (measles, mumps, rubella) into three separate shots.
  • He questioned giving the Hepatitis B vaccine to newborns in the first 24 hours of life.
  • And, in an unusual twist, he promoted leucovorin (a form of folinic acid, often used in cancer care) as a potential treatment for autism symptoms.

What Science Actually Shows on Tylenol

  • No proven link: A 2024 Swedish study of 2.5 million children found no causal connection between prenatal acetaminophen use and autism.
  • Mixed signals: A 2025 review of 46 studies suggested there might be associations, but experts say that does not prove causation.
  • Medical advice remains the same: Groups like the American College of Obstetricians and Gynecologists still consider acetaminophen the safest pain/fever medicine during pregnancy — when used at the lowest dose, for the shortest time.

Expert Reactions on Trump Tylenol debate

  • Coalition of Autism Scientists: “The data cited do not support the claim that Tylenol causes autism.”
  • Kenvue: “We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers and parents.”
  • UK Health Regulator: Paracetamol (the same drug outside the U.S.) is safe and there is no autism evidence.

Autism researcher Dr. Diana Schendel said the Tylenol–autism question has been studied for years: “Without showing new evidence, these announcements become reckless and potentially harmful.”

Market Impact

  • Kenvue stock (KVUE) plunged over 7% after Trump’s remarks but recovered 5% in late trading.
  • Johnson & Johnson (JNJ), the former parent company, also saw minor volatility.
  • Analysts say the absence of new science means the stock should stabilize, though lawsuits over Tylenol and autism claims could continue.

Why This Matters

  • Pregnant women are confused: The president’s advice contradicts official medical guidance.
  • Vaccine fears resurface: Trump and RFK Jr.’s comments revived the long-debunked theory linking vaccines to autism — a claim rejected by decades of global research.
  • Autism advocacy groups worry the announcement fuels fear while giving false hope about treatments like leucovorin.

Trump’s announcement has once again pushed controversial, unproven medical claims into the spotlight. While Tylenol lawsuits and studies keep the debate alive, the scientific consensus is clear: acetaminophen does not cause autism and vaccines remain safe, saving millions of lives.

👉 Expect the FDA to review Tylenol labels and the debate to continue — but for now, experts urge pregnant women to follow their doctor’s advice, not political speeches.

Read Checkout this post: Tylenol, Autism & Trump: Panic, Stocks, and a New Wave of Questions

Read more at: Todaybeat.com

Categories
Top Stories Entertainment Lifestyle World News 🔥 Trending

71st National Film Awards 2025: SRK Finally Wins His First National Award for Jawan, Vikrant Massey Joins Him

New Delhi, Sept 23, 2025: Bollywood’s King Khan finally did it. After more than three decades of ruling hearts and box office records, Shah Rukh Khan (SRK) won his first ever National Award for acting. He received the honour for his blockbuster film Jawan at the *71st National Film Awards 2025.

What made the moment even more special was that he shared the Best Actor award with Vikrant Massey, who won for his brilliant performance in 12th Fail.


The Shah Rukh Khan, SRK’s Emotional Win

For years, SRK fans had been waiting for this recognition. While he has bagged countless Filmfare and international awards, the National Award always felt missing from his trophy cabinet. His powerful role in Jawan not only set the box office on fire but also gave him the credibility of India’s top honour in cinema.

On social media, fans called it “long overdue” and “a moment of justice.” Many said it was the perfect crown on his already legendary career.


Vikrant Massey’s Big Leap with Shah Rukh Khan

Sharing the award with SRK, Vikrant Massey proved that talent speaks louder than anything else. From television beginnings to serious cinema, his journey has been inspiring. 12th Fail, based on a true story, connected with millions and brought him the recognition he deserved.


Rani Mukerji and Mohanlal Shine

The awards night also saw Rani Mukerji win Best Actress for Mrs. Chatterjee vs Norway, a film that touched hearts with its raw storytelling.

The biggest lifetime honour, the Dadasaheb Phalke Award, went to Malayalam superstar Mohanlal, celebrating his decades of contribution to Indian cinema. His acceptance speech was full of humility, reminding everyone why he is one of the greatest actors of our times.


Why This Awards Night Stands Out other then Shah Rukh Khan

This year’s National Awards celebrated both mainstream blockbusters like Jawan and content-driven films like 12th Fail. It showed that Indian cinema is big enough to reward commercial success as well as meaningful storytelling.

SRK’s win will be remembered as a turning point — proof that even after 30 years, he can reinvent himself and still surprise audiences. Vikrant’s win, on the other hand, is a signal to young actors that hard work and persistence do pay off.


Bottom Line

The 71st National Film Awards will go down in history as the night SRK finally got his long-awaited National Award, Vikrant Massey joined the big league, and legends like Rani Mukerji and Mohanlal added new feathers to their caps.

For fans, it wasn’t just about awards — it was about emotion, legacy, and the magic of cinema.

Read more at: TodayBeat.com

Categories
Stock Market Top Stories 🔥 Trending

Investors Rush for GK Energy IPO – GMP Buzzing at 20%! Should You Expect a Jackpot

New Delhi, September 23, 2025: The ₹464 crore GK Energy IPO has closed today and it turned out to be a blockbuster. The issue was subscribed nearly 90 times, which clearly shows how much investors trusted this company. Now all attention is on September 26, when the shares will hit the market.

Quick GK Energy IPO Details

The company had fixed a price band of ₹145 to ₹153 per share. A lot contained 98 shares, which meant retail investors had to invest at least ₹14,994. In total, the issue size was about ₹464.26 crore. The stock will get listed on both NSE and BSE.

Big Subscription Numbers for GK Energy IPO

  • Institutions (QIBs): 186.29×
  • HNIs: 122.73×
  • Retail Investors: 20.79×

It’s not just the big institutions, even small investors rushed in. This mix of retail and institutional demand is what makes this IPO stand out.

Grey Market Premium Buzz for GK Energy IPO

Right now, the Grey Market Premium (GMP) is about ₹20 per share above the issue price. That signals a likely 13% listing gain.

Some reports even claim the GMP touched ₹31, which, if true, means the stock could list with almost 20% upside. In simple terms, the share may open somewhere between ₹173 and ₹184, if this trend continues.

Why Investors Are So Interested in GK Energy IPO

First, the company is part of the renewable energy sector, and that’s one of the hottest themes in India today. Everyone is talking about clean and green energy, and GK Energy fits right in.

Second, the kind of oversubscription we saw tells us that confidence is high. When both retail and big investors chase an IPO, it usually creates a buzz in the market.

And third, many are simply looking for listing gains. GMP has been steady, which gives traders hope for good profits on the first day.

Things You Should Keep in Mind about GK Energy IPO

Of course, GMP is not official. It changes quickly and sometimes doesn’t match the actual listing price. On listing day, a lot of traders may sell immediately, which can make the stock very volatile.

For long-term investors, the real story will depend on how GK Energy performs in terms of profits and how much the government supports renewable projects in the coming years.

How to Buy GK Energy Shares

The IPO has closed, but you can still buy GK Energy shares once they list on September 26, 2025 on NSE and BSE. Here’s how:

  1. Wait for Listing – Shares will start trading on NSE and BSE like any other stock.
  2. Open a Demat + Trading Account – With brokers like Zerodha, Groww, Upstox, ICICI Direct, or HDFC Securities.
  3. Search for GK Energy – On your broker’s app/website, type the stock name or symbol.
  4. Place a Buy Order – Use a market order to buy at current price or a limit to set your price.

⚠️ Note

  • Listing Day = Volatility. Prices can move up and down fast.
  • Short-term traders may book profits quickly.
  • Long-term investors should focus on company growth, not just Day 1 excitement.

Final Word

The GK Energy IPO has already created a storm with heavy oversubscription and a strong grey market buzz. A double-digit listing gain looks possible, but only the market on September 26 will give the final answer.

Whether it opens at 13% or even 20% higher, this IPO has already secured a place as one of the most exciting listings of 2025.

Related Reading on TodayBeat

If you follow stock market and business news regularly, don’t miss our coverage on TodayBeat.com. We track the latest IPOs, market updates, and breaking financial stories

Exit mobile version